Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.

NCT Number	NCT07700979
Lead Sponsor	Akeso
Conditions	Gastric / Gastroesophageal Junction Adenocarcinoma
Enrollment	900 participants
Start Date	2026-08-20
Primary Completion	2029-08-18 (estimated)
Study Completion	2030-08-18 (estimated)
Updated on ClinicalTrials.gov	2026-07-14